<DOC>
	<DOCNO>NCT01541280</DOCNO>
	<brief_summary>Patients include study high risk acute myeloid leukemia myelodysplastic syndrome define receive allogeneic transplantation condition either myeloablative reduced regimen . Following allogeneic transplantation , patient receive maintenance regimen combine chemotherapy azacitidine ( aza ) immunotherapy donor lymphocyte infusion .</brief_summary>
	<brief_title>VIDAZA-DLI Pre-emptive Azacitidine Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation High Risk Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients high risk acute myeloid leukemia undergo allogeneic transplantation either familial unrelated donor . High risk AML define : AML CR1 unfavorable cytogenetics define complex caryotype , autosomal monosomy combine cytogenetics abnormality inv ( 3 ) /t ( 3,3 ) , ( 6 ; 9 ) , ( 6 ; 11 ) , ( 11 ; 19 ) , del ( 5q ) , del ( 7q ) . AML CR2 great remission prior allogeneic transplantation AML PR relapse prior allogeneic transplantation Or Patients high risk myelodysplastic syndrome undergo allogeneic transplantation either familial unrelated donor . High risk MDS define : MDS intermediate2 group high risk group accord IPSS criterion Age 18 70 year . Availability HLA identical family donor unrelated donor match 10/10 allele ( HLAA , B , C , DRB1 , DQB1 ) maximum 1 allele antigen mismatch OR family donor maximum 1 allele mismatch . Conditioning regimen allogeneic transplantation may either myeloablative reduce . Be able understand sign inform consent . Affiliation number National Health Care System Men woman childbearing potential must use effective contraception 3 month treatment . The presence one exclusion criterion render patient ineligible : Patient full relapse posttransplant ( &gt; 20 % blast bone marrow ) follow allogeneic transplant Documented leukemic infiltration CNS/cerebrospinal fluid . Karnofsky performance score 60 % . Acute chronic heart failure ( NYHA Class III IV ) symptomatic ischemic heart disease . follow allogeneic transplant Severe liver failure ( bilirubin &gt; 30 μmoles/L , SGPT &gt; 4 X upper limit normal ) . Hepatic malignancy advance stage . Severe neurological psychiatric disorder Acute GVHD grade IIIII . Patient grade I GVHD may include ( see annex 1 GHVD grade definition ) . Active uncontrolled infection . Denied informed consent . Treatment investigational drug follow allogeneic transplantation . No effective contraception Lactating female Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Allogreffe , LAM , MDS</keyword>
	<keyword>Azacitidine ( VidazaÒ )</keyword>
	<keyword>Injection de lymphocyte de donneur ( DLI )</keyword>
</DOC>